Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

3.6K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.6K
Hematopoiesis01:21

Hematopoiesis

7.7K
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
7.7K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

636
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
636
Overview of Hematopoiesis01:20

Overview of Hematopoiesis

6.5K
Hematopoiesis, or blood cell production, is a vital biological process that begins early in embryonic development and continues throughout life. This process generates the various types of cells found in blood, including red blood cells, white blood cells, and platelets from hematopoietic stem cells (HSCs).
Developmental Phases of Hematopoiesis
Initially, HSCs are formed in the embryonic yolk sac, a critical site for early blood cell production. These stem cells subsequently migrate to other...
6.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Retrospective review of the toxicities and change in dosing patterns for pegaspargase in patients with acute lymphoblastic leukemia/lymphoma and T-cell lymphoma.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2024
Same author

Establishing clinical pharmacist telehealth services during the COVID-19 pandemic.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2021
Same author

Venetoclax as a therapeutic option for the treatment of chronic lymphocytic leukemia: the evidence so far.

Expert opinion on pharmacotherapy·2021
Same author

Biomarker BINGO.

Journal of the advanced practitioner in oncology·2021

Related Experiment Video

Updated: Nov 17, 2025

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis
03:40

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

Published on: December 8, 2023

1.5K

2018-2019 Drug Updates in Hematologic Malignancies.

Lauren Held1

  • 1Seattle Cancer Care Alliance, Seattle, Washington.

Journal of the Advanced Practitioner in Oncology
|February 18, 2021
PubMed
Summary

This review covers recent FDA-approved therapies for blood cancers, including clinical trial data and practical guidance on safe administration and managing side effects.

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Hematologic malignancies represent a significant area of cancer research.
  • The landscape of cancer therapeutics is rapidly evolving with new drug approvals.
  • Effective management requires staying abreast of the latest treatment options.

Purpose of the Study:

  • To provide an update on FDA-approved therapies for hematologic malignancies.
  • To review supporting clinical trial data for these new therapies.
  • To discuss best practices for the safe and effective use of these agents.

Main Methods:

  • Literature review of FDA approvals in the past year.
  • Analysis of clinical trial data supporting new indications.
  • Synthesis of expert recommendations on dosing, administration, monitoring, and adverse event management.

More Related Videos

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells
12:04

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Published on: March 10, 2023

4.2K
Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis
06:28

Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis

Published on: November 10, 2023

3.0K

Related Experiment Videos

Last Updated: Nov 17, 2025

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis
03:40

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

Published on: December 8, 2023

1.5K
Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells
12:04

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Published on: March 10, 2023

4.2K
Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis
06:28

Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis

Published on: November 10, 2023

3.0K

Main Results:

  • Several new FDA-approved therapies for initial or expanded indications in hematologic malignancies were identified.
  • Supporting clinical trial data demonstrated efficacy and safety profiles.
  • Key considerations for safe and effective use, including dosing, administration, monitoring, and adverse event management, were outlined.

Conclusions:

  • Staying current with FDA-approved therapies is crucial for optimal patient care in hematologic malignancies.
  • Evidence-based best practices are essential for maximizing treatment benefits and minimizing risks.
  • This update provides valuable information for clinicians managing patients with blood cancers.